ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 7.370-7.640 for the period, compared to the consensus earnings per share estimate of 6.970. The company issued revenue guidance of $854.0 million-$873.0 million, compared to the consensus revenue estimate of $869.3 million. ANI Pharmaceuticals also updated its FY 2026 guidance to EPS.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of recent analyst reports. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. boosted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, HC Wainwright increased their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.14.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $82.28 on Wednesday. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 50.48 and a beta of 0.51. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The business’s 50 day simple moving average is $82.37 and its 200-day simple moving average is $83.54. ANI Pharmaceuticals has a 12 month low of $53.35 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period last year, the business posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $82.32, for a total value of $32,928.00. Following the sale, the vice president directly owned 74,874 shares in the company, valued at $6,163,627.68. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the transaction, the senior vice president owned 58,564 shares of the company’s stock, valued at $4,825,673.60. This represents a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 27,601 shares of company stock worth $2,410,898. 12.70% of the stock is owned by company insiders.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI issued strong FY‑2026 guidance: total net revenues of $1,055M–$1,115M, Cortrophin Gel sales $540M–$575M, adjusted EBITDA $275M–$290M, and plans a ~90‑person Rare Disease commercial expansion — a clear growth roadmap that underpins the recent rally. ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
• Positive Sentiment: Analyst coverage highlights the strength: Seeking Alpha notes a robust 2025 finish and calls the 2026 guidance bullish (60% revenue growth y/y driven by Cortrophin Gel), points to strong liquidity (~$285M) and a relatively low forward P/E (~11.2x) versus peers. ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance
• Neutral Sentiment: Technical/volume note — Zacks flagged a recent ~10.6% intraday jump on above‑average volume but cautioned that recent estimate revisions may not guarantee further short‑term gains; this suggests elevated volatility after the guidance‑driven move. Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength?
• Neutral Sentiment: Reported short interest data in recent filings appears non‑informative (zeros/NaN), so short activity is unlikely to explain the move; treat reported figures with caution.
• Negative Sentiment: News outlets report the stock pulling back today after the rally — likely profit‑taking and intraday repositioning as investors digest aggressive 2026 targets and increased commercial spend. This intra‑session weakness is driving the decline. ANI Pharmaceuticals (ANIP) stock trades down, here is why

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after buying an additional 423 shares during the period. Jane Street Group LLC acquired a new stake in ANI Pharmaceuticals in the 1st quarter worth about $2,706,000. Finally, Norges Bank acquired a new stake in ANI Pharmaceuticals in the 2nd quarter worth about $625,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.